Edith Cowan University

About: Edith Cowan University is a education organization based out in Perth, Western Australia, Australia. It is known for research contribution in the topics: Population & Context (language use). The organization has 4040 authors who have published 13529 publications receiving 339582 citations. The organization is also known as: Edith Cowan & ECU.

Reliability of performance measurements derived from ground reaction force data during countermovement jump and the influence of sampling frequency.

Abstract: Force platforms are used extensively to measure force and power output during countermovement jump (CMJ). The purpose of this study was to examine measurement reliability and validity of commonly used performance measurements derived from ground reaction force (GRF)-time data during CMJ and the influence of sampling at different frequencies. Twenty-four men performed 2 trials of CMJ on a force platform, and GRF-time data were sampled at a rate of 500 Hz. Data obtained at 500 Hz were considered as the reference, and then data were resampled at 400, 250, 200, 100, 50, and 25 Hz, using interpolation. Commonly used power, force, and velocity performance measures were obtained from GRF-time data. Reliability was assessed by intraclass correlation coefficient (ICC) and coefficient of variation (CV) between the 2 trials within the session. Peak power, peak force, and peak velocity were highly reliable across all sampling frequencies (ICC = 0.92-0.98, CV = 1.3-4.1). Percentage differences from 500-Hz reference values ranged from -0.85 to 0.20% at 400 Hz, -1.88 to 0.89% at 250 Hz, -1.80 to 1.31% at 200 Hz, -3.63 to 3.34% at 100 Hz, -11.37 to 6.51% at 50 Hz, and -13.17 to 9.03% at 25 Hz. In conclusion, peak power, force, and velocity measurements derived from GRF to assess leg extensor capabilities are reliable within a test session except for peak rate of force development and time to peak power. With regard to sampling frequency, scientists and practitioners may consider sampling as low as 200 Hz, depending on the purpose of measurement, because the percentage difference is not markedly enlarged until the frequency is 100 Hz or lower.

Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology : a longitudinal study

Abstract: Summary Background Brain amyloid β (Aβ) deposition and neurodegeneration have been documented in about 50–60% of cognitively healthy elderly individuals (aged 60 years or older). The long-term cognitive consequences of the presence of Alzheimer's disease pathology and neurodegeneration, and whether they have an independent or synergistic effect on cognition, are unclear. We aimed to characterise the long-term clinical and cognitive trajectories of healthy elderly individuals using a two-marker (Alzheimer's disease pathology and neurodegeneration) imaging construct. Methods Between Nov 3, 2006, and Nov 25, 2014, 573 cognitively healthy individuals in Melbourne and Perth, Australia, (mean age 73·1 years [SD 6·2]; 58% women) were enrolled in the Australian Imaging, Biomarker and Lifestyle (AIBL) study. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by PET, and neurodegeneration (N) was established by measuring hippocampal volume using MRI. Individuals were categorised as A − N − , A + N − , A + N + , or suspected non-Alzheimer's disease pathophysiology (A − N + , SNAP). Clinical progression, hippocampal volume, standard neuropsychological tests, and domain-specific and global cognitive composite scores were assessed over 6 years of follow-up. Linear mixed effect models and a Cox proportional hazards model of survival were used to evaluate, compare, and contrast the clinical, cognitive, and volumetric trajectories of patients in the four AN categories. Findings 50 (9%) healthy individuals were classified as A + N + , 87 (15%) as A + N − , 310 (54%) as A − N − , and 126 (22%) as SNAP. APOE e4 was more frequent in participants in the A + N + (27; 54%) and A + N − (42; 48%) groups than in the A − N − (66; 21%) and SNAP groups (23; 18%). The A + N − and A + N + groups had significantly faster cognitive decline than the A − N − group (0·08 SD per year for AIBL-Preclinical AD Cognitive Composite [PACC]; p + N + group also had faster hippocampal atrophy than the A − N − group (0·04 cm 3 per year; p=0·02). The SNAP group generally did not show significant decline over time compared with the A − N − group (0·03 SD per year [p=0·19] for AIBL-PACC and a 0·02 cm 3 per year increase [p=0·16] for hippocampal volume), although SNAP was sometimes associated with lower baseline cognitive scores (0·20 SD less than A − N − for AIBL-PACC). Within the follow-up, 24% (n=12) of individuals in the A + N + group and 16% (n=14) in the A + N − group progressed to amnestic mild cognitive impairment or Alzheimer's disease, compared with 9% (n=11) in the SNAP group. Interpretation Brain amyloidosis, a surrogate marker of Alzheimer's disease pathology, is a risk factor for cognitive decline and for progression from preclinical stages to symptomatic stages of the disease, with neurodegeneration acting as a compounding factor. However, neurodegeneration alone does not confer a significantly different risk of cognitive decline from that in the group with neither brain amyloidosis or neurodegeneration. Funding CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF), National Health and Medical Research Council, the Dementia Collaborative Research Centres programme, McCusker Alzheimer's Research Foundation, and Operational Infrastructure Support from the Government of Victoria.

Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease

Abstract: High amyloid has been associated with substantial episodic memory decline over 18 and 36 months in healthy older adults and individuals with mild cognitive impairment. However, the nature and magnitude of amyloid-related memory and non-memory change from the preclinical to the clinical stages of Alzheimer's disease has not been evaluated over the same time interval. Healthy older adults (n = 320), individuals with mild cognitive impairment (n = 57) and individuals with Alzheimer's disease (n = 36) enrolled in the Australian Imaging, Biomarkers and Lifestyle study underwent at least one positron emission tomography neuroimaging scan for amyloid. Cognitive assessments were conducted at baseline, and 18- and 36-month follow-up assessments. Compared with amyloid-negative healthy older adults, amyloid-positive healthy older adults, and amyloid-positive individuals with mild cognitive impairment and Alzheimer's disease showed moderate and equivalent decline in verbal and visual episodic memory over 36 months (d's = 0.47-0.51). Relative to amyloid-negative healthy older adults, amyloid-positive healthy older adults showed no decline in non-memory functions, but amyloid-positive individuals with mild cognitive impairment showed additional moderate decline in language, attention and visuospatial function (d's = 0.47-1.12), and amyloid-positive individuals with Alzheimer's disease showed large decline in all aspects of memory and non-memory function (d's = 0.73-2.28). Amyloid negative individuals with mild cognitive impairment did not show any cognitive decline over 36 months. When non-demented individuals (i.e. healthy older adults and adults with mild cognitive impairment) were further dichotomized, high amyloid-positive non-demented individuals showed a greater rate of decline in episodic memory and language when compared with low amyloid positive non-demented individuals. Memory decline does not plateau with increasing disease severity, and decline in non-memory functions increases in amyloid-positive individuals with mild cognitive impairment and Alzheimer's disease. The combined detection of amyloid positivity and objectively-defined decline in memory are reliable indicators of early Alzheimer's disease, and the detection of decline in non-memory functions in amyloid-positive individuals with mild cognitive impairment may assist in determining the level of disease severity in these individuals. Further, these results suggest that grouping amyloid data into at least two categories of abnormality may be useful in determining the disease risk level in non-demented individuals.

Sustainable third-party reverse logistic provider selection with fuzzy SWARA and fuzzy MOORA in plastic industry

Abstract: Third-party logistic provider (3PLP) companies play a major role in supply chain management (SCM) by carrying out specialized functions—namely, integrated operation, warehousing, and transportation services. Taking sustainability issues into consideration makes reverse logistics even more significant. In this paper, a combination of sustainability and risk factors was considered for third-party reverse logistic provider (3PRLP) evaluation. Initially, fuzzy step-wise weight assessment ratio analysis (Fuzzy SWARA) was applied for weighing the evaluation criteria; then, Fuzzy multi-objective optimization on the basis of ratio analysis (Fuzzy MOORA) was utilized for ranking the sustainable third-party reverse logistic providers in the plastic industry in the second step. Findings highlight that quality, recycling, health, and safety were the most important criteria in economic, environmental, and social dimensions of sustainability, respectively. Also, operational risk was found to have the highest weight among risk factors.